Inhibace (Cilazapril)

Cilazapril blocks the angiotensin‑converting enzyme, which stops the conversion of angiotensin I into angiotensin II. With less angiotensin II, blood vessels relax, aldosterone secretion falls, and the body retains less sodium and water, leading to lower blood pressure and reduced strain on the heart.

The appropriate dose of Inhibace is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose on their own.

Safety of cilazapril in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a healthcare provider after careful evaluation.

To place an order, submit an enquiry on the Inhibace product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inhibace (cilazapril) belongs to the same class as enalapril, lisinopril and ramipril. All share a common mechanism of ACE inhibition, but they differ in pharmacokinetic profiles, dosing frequency and individual tolerability. Choice of agent is usually based on physician preference, patient response and specific safety considerations.

Inhibace tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Inhibace is taken orally, usually once daily or as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water, and it can be taken with or without food unless otherwise advised by the prescriber.

The most serious adverse reactions include angioedema, which can affect the airway, severe hyperkalemia, acute kidney injury, and rare cases of severe neutropenia or liver injury. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing.

Inhibace is contraindicated in patients with a known hypersensitivity to cilazapril or any ACE inhibitor, a history of angioedema related to ACE‑inhibitor therapy, and in those with severe renal impairment or hyperkalemia that cannot be corrected. Pregnant women should avoid it unless clearly indicated.